XML 45 R22.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION
15. SEGMENT INFORMATION

Edwards Lifesciences conducts operations worldwide and is managed in the following four reportable segments: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's operating segments are organized primarily based on economic characteristics as well as other characteristics, including types of customers, nature of the regulatory environment, and product offerings.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (“CODM”), which is the Company's Chief Executive Officer. The CODM evaluates the performance of the Company's reportable segments based on segment net sales and segment operating income. The CODM considers budget or forecast-to-actual results variances for segment operating income on a periodic basis for evaluating the performance of each segment and making decisions about allocating capital and other resources to each segment.
Segment net sales are based on actual foreign exchange rates. Segment expenses and segment operating income are based on internally derived foreign exchange rates and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. There were no customers that represented 10% or more of the Company's total net sales.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate research and development expenses, manufacturing variances, corporate headquarters costs, net interest income, global marketing expenses, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, most of the Company's amortization, and a portion of the Company's depreciation expense. The CODM does not receive information on total assets by reportable segment.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Segment Net Sales    
United States$889.7 $806.4 $1,728.6 $1,588.5 
Europe378.2 332.2 720.0 658.2 
Japan95.3 86.5 177.1 172.5 
Rest of World169.0 144.3 319.2 280.1 
Total segment net sales$1,532.2 $1,369.4 $2,944.9 $2,699.3 
Cost of Sales
United States$167.5 $146.4 $313.5 $286.1 
Europe84.8 74.4 167.0 148.0 
Japan13.6 12.6 25.9 24.4 
Rest of World43.9 40.3 83.7 78.7 
Total segment cost of sales$309.8 $273.7 $590.1 $537.2 
Selling, general, and administrative expenses
United States$135.7 $117.8 $268.9 $233.0 
Europe74.2 70.9 147.6 142.3 
Japan18.5 19.6 34.9 45.6 
Rest of World48.3 46.6 90.4 88.0 
Total segment selling, general, and administrative expenses$276.7 $254.9 $541.8 $508.9 
Other Segment Items
United States$0.6 $0.7 $1.2 $1.4 
Europe15.2 0.8 6.9 4.9 
Japan(0.2)(3.6)(4.8)(2.9)
Rest of World(7.9)(3.0)(17.1)(4.1)
Total other segment items (a)
$7.7 $(5.1)$(13.8)$(0.7)
Segment Operating Income    
United States$585.9 $541.5 $1,145.0 $1,068.0 
Europe204.0 186.1 398.5 363.0 
Japan63.4 57.9 121.1 105.4 
Rest of World84.7 60.4 162.2 117.5 
Total segment operating income$938.0 $845.9 $1,826.8 $1,653.9 
_______________________________________________________________________________
(a)    Other segment items include research and development expenses and foreign currency.
The table below presents a reconciliation of segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Pre-tax Income Reconciliation    
Segment operating income$938.0 $845.9 $1,826.8 $1,653.9 
Unallocated amounts:    
Corporate items(505.2)(480.8)(991.4)(927.8)
Separation costs (Note 3)
(4.2)— (8.4)— 
Certain litigation expenses(15.5)(8.1)(26.4)(17.0)
Foreign currency(1.9)9.5 5.4 6.4 
Consolidated operating income411.2 366.5 806.0 715.5 
Non-operating income(11.0)17.5 28.1 39.7 
Consolidated pre-tax income$400.2 $384.0 $834.1 $755.2 

Enterprise-wide Information
(in millions)

Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements. Refer to the segment information above for United States net sales. Sales within any other individual country were less than 10 percent of the Company's consolidated net sales for all periods presented.

 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Net Sales by Major Product Group    
Transcatheter Aortic Valve Replacement$1,130.9 $1,038.6 $2,177.5 $2,046.5 
Transcatheter Mitral and Tricuspid Therapies134.5 83.0 249.7 155.9 
Surgical Structural Heart266.8 247.8 517.7 496.9 
$1,532.2 $1,369.4 $2,944.9 $2,699.3